News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS)'s Serelaxin Should Not Be Approved For Heart Failure: FDA Staff


3/26/2014 8:06:50 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

A drug to treat acute heart failure made by Novartis AG should not be approved because there is insufficient evidence to show it improves symptoms, according to an initial review by the U.S. Food and Drug Administration. The review, posted on the FDA's website on Tuesday, comes two days ahead of a meeting of outside advisors who will make their own recommendation on whether the drug should be approved. The FDA is not obliged to follow the advice of its advisory panels but typically does so.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Forbes
Read at Bloomberg
Read at RTT News
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES